SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Pharm Country
TG Therapeutics Announces Triple Combination Data Presentations at the at the 62nd American Society of Hematology Annual Meeting
December 7, 2020
 · 
7 min read
Drug Development
Clinical Catch-Up: November 30-December 4
December 4, 2020
 · 
8 min read
 · 
Mark Terry
Pharm Country
TG Therapeutics Recaps Schedule of Data Presentations at the Upcoming 62nd American Society of Hematology Annual Meeting and Exposition
December 3, 2020
 · 
5 min read
Drug Development
TG Therapeutics Announces Publication of Phase 2 Data Evaluating Umbralisib in Patients with Chronic Lymphocytic Leukemia Who Are Intolerant to Prior BTK or PI3K Inhibitor Therapy in Blood
December 2, 2020
 · 
5 min read
Pharm Country
TG Therapeutics Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration for Ublituximab in Combination with Umbralisib as a Treatment for Patients with Chronic Lymphocytic Leukemia
December 1, 2020
 · 
8 min read
Pharm Country
TG Therapeutics to Participate in the 3rd Annual Evercore ISI HealthCONx ConferenceFireside chat scheduled for Tuesday, December 1, 2020 at 10:05 AM ET
November 30, 2020
 · 
1 min read
Pharm Country
TG Therapeutics to Participate in the Jefferies Virtual London Healthcare ConferenceFireside chat scheduled for Tuesday, November 17, 2020 at 2:20 PM ET/ 7:20 PM GMT
November 13, 2020
 · 
1 min read
Business
TG Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results
November 9, 2020
 · 
11 min read
Pharm Country
TG Therapeutics Highlights Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting
November 4, 2020
 · 
10 min read
Pharm Country
TG Therapeutics Announces Data Presentations at the Upcoming 62nd American Society of Hematology Annual Meeting and ExpositionZoom conference call to be held November 5, 2020 at 8:45 AM ET
November 2, 2020
 · 
7 min read
Pharm Country
TG Therapeutics Announces Fast Track Designation Granted by the FDA to Ublituximab in Combination with Umbralisib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia
October 21, 2020
 · 
6 min read
Pharm Country
TG Therapeutics to Present at Upcoming Investor Conferences
September 9, 2020
 · 
2 min read
Policy
TG Therapeutics Announces FDA Acceptance of New Drug Application for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma and Follicular Lymphoma
August 13, 2020
 · 
7 min read
Business
TG Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results
August 10, 2020
 · 
10 min read
Pharm Country
TG Therapeutics to Host Conference Call on Second Quarter 2020 Financial Results and Business UpdateInvestor Conference Call to be held Monday, August 10, 2020 at 8:30 AM ET
August 6, 2020
 · 
1 min read
Pharm Country
TG Therapeutics Announces Publication in Blood Advances Describing Unique Immunomodulatory Effects on CLL T cells by Umbralisib
July 8, 2020
 · 
4 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS